Biofrontera Pharmaceuticals GmbH
Hemmelrather Weg 201
Leverkusen
51377
Germany
Tel: 49-0-214-876320
Fax: 49-0-214-87632-90
Website: http://www.biofrontera.com/
Email: info@biofrontera.de
6 articles about Biofrontera Pharmaceuticals GmbH
-
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
11/10/2022
Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of the U.S. financial markets on Monday, November 14, 2022.
-
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
-
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
9/29/2022
Biofrontera Inc. announced that Erica Monaco, Chief Executive Officer, will present at the Roth Inaugural Healthcare Opportunities Conference being held at the Yale Club in New York City on October 6, 2022.
-
Auron Therapeutics reels in $48 million to identify novel AI-based cancer targets, Frontera scoops up $160 million for AAV gene therapy and tech manufacturing and MMI scores $75 million for robotic microsurgery.
-
DUSA Pharmaceuticals, Inc. Files Lawsuit Against Biofrontera Inc. for Patent Infringement, Trade Secret Misappropriation, and Tortious Interference
7/11/2018
The lawsuit alleges patent infringement of DUSA's patents covering DUSA's product for topical solution, 20% used with DUSA's BLU-U Blue Light Photodynamic Therapy Illuminator.
-
Biofrontera Strengthens Its Dermatology Drug Pipeline By Acquiring A Phase II Compound
10/7/2004